Please ensure Javascript is enabled for purposes of website accessibility

Cathie Wood Bought This Stock for a Bargain. Should You Follow?

By Adria Cimino - Jun 17, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is one of Wood's biggest biotech holdings.

Star investor Cathie Wood is usually one to follow. The founder of ARK Invest has watched her biggest fund gain nearly five times more than the S&P 500 over the past five years. But what about when Wood goes for a company that's disappointing investors?

That's the case with Vertex Pharmaceuticals (VRTX -1.24%). In less than a year, the biotech company ended development of two candidates in one of its rare-disease programs. After news broke of the latest to go, the stock sank more than 11% in one trading session.

That's when Wood moved to increase her Vertex holdings. The stock is among the top 10 holdings in the ARK Genomic Revolution ETF. Now the question is, should you follow Wood's lead and consider shares of this biotech company?

A person sitting at a cafe works on a laptop.

Image source: Getty Images.

More than $6 billion in revenue

First, a little background about the company. Vertex is the leader in cystic fibrosis (CF) treatment. The company last year made $6.2 billion from its CF portfolio. In late 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's newest drug, Trikafta. It became a blockbuster the next year.

The drug could be an important revenue driver in the coming years because it has the potential to treat more than 90% of all CF patients. Revenue will grow progressively from today as Vertex wins approvals in different countries and age groups.

Morningstar predicts $7 billion in sales this year for Vertex, and Trikafta will lead the way. Thanks to booming sales, Vertex has been profitable for the past four years -- and last year reported more than $2.7 billion in net income.

This is all very positive, but investors are concerned about what will happen when increases in CF sales start to slow. At a certain point, Vertex will have reached most potential patients. CF is a rare disease, so once Vertex serves all of today's market, the number of new patients over time will be limited.

Eyes have been on two pipeline programs in particular: treatments for rare lung and liver disorder alpha-1 antitrypsin deficiency (AATD), and gene editing for blood disorders. AATD has spurred Vertex's share-price woes over the past year. The company ended development of one candidate last fall and a second candidate this month, which was the reason for the recent share decline. Vertex said it would bring other AATD candidates into trials next year.

A normal part of drug development

Vertex has said that testing several candidates -- and seeing failures -- is a normal part of drug development, and that's true. It wouldn't be realistic to expect every candidate to be successful. And it wouldn't be realistic to expect success in a new treatment area to happen overnight, either. That's why long-term investors shouldn't be alarmed over the AATD news at this point.

At the same time, Vertex's results in its gene-editing program for blood disorders sickle cell disease and beta thalassemia are encouraging. The company offered an update this month. In a follow-up after more than three months on 22 patients, all of them showed "consistent and sustained" response to the therapy. And more good news is that this is Vertex's most advanced program outside of CF. The company aims to file for regulatory approval in the coming 18 to 24 months.

Today, stem-cell transplants are the only cure for the two blood disorders. But they are complicated and not options for everyone. Vertex is hoping its one-time gene-editing therapy may offer another option.

Unfortunately, investors' concern over AATD has outweighed their optimism about the gene-editing program. Vertex shares have dropped about 20% so far this year.

Is this an opportunity?

For Cathie Wood, this created opportunity. Vertex's shares are trading at about 17 times forward earnings estimates. That's the lowest since at least January 2020.

VRTX PE Ratio (Forward) Chart

VRTX PE Ratio (Forward) data by YCharts.

Now let's get back to our original question. Should this also create a buying opportunity for other long-term investors?

My answer is "yes," and here's why: We can expect strong CF revenue from Vertex for several years. Vertex even predicts its CF leadership will last through the late 2030s. The billions in dollars of revenue will fund pipeline programs, and we can add to that Vertex's $6.9 billion in cash. This amount of cash even offers Vertex the possibility to buy a close-to-market candidate at any point.

If Vertex is successful with AATD, that would be a plus. But I'm particularly interested in the gene-editing therapy for blood disorders. It's closer to market and could be a game changer.

Vertex may not deliver big gains this month or even this year. But investors who favor buying and holding are likely to reap rewards further down the road, so they may be very happy about their decision to follow Cathie Wood.

Adria Cimino owns shares of Vertex Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$299.23 (-1.24%) $-3.77
ARK ETF Trust - ARK Genomic Revolution ETF Stock Quote
ARK ETF Trust - ARK Genomic Revolution ETF
ARKG
$38.64 (-5.13%) $-2.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.